Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JEWEL-101: XB002 in Advanced Solid Tumors
NCT04925284Phase 1Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 1, open-label trial of samatatatug zovodotin in non-small cell lung cancer (NSCLC), Cervical Cancer (CC), squamous cell carcinoma of the head and neck (HNSCC) and 8 more (5 arms), sponsored by Exelixis, Inc. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose at 18 months and Objective Response Rate at 12 months. Started Jun 2021; status: completed.
02
Drugs
samatatatug zovodotin
03
Conditions
non-small cell lung cancer (NSCLC)Cervical Cancer (CC)squamous cell carcinoma of the head and neck (HNSCC)pancreatic cancer (PC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04925284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925284.